Please login to the form below

Not currently logged in

Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands

The latest healthcare comms movers

Astellas comms chief moves on to Cello

Jo Taylor

Cello Health Communications is upping its communications ante, appointing pharma veteran Jo Taylor (pictured) to head up its corporate affairs function.

Taylor joins the agency from Astellas, where she was senior director of corporate communications, EMEA.

She has also served in various positions for Daiichi Sankyo, Novartis, Eli Lilly and GlaxoSmithKline.

Commenting on her new venture, Taylor said: “I am very excited about joining Cello, not least because I have such a talented team around me.

“I believe what we offer at Cello Health Corporate Affairs is quite unique in the industry because we have walked in the shoes of the Corporate Affairs Director, set up and run those very departments in global pharma companies and we therefore completely understand the challenges they face.

This means that the solutions we develop are not only very effective but they are presented in a way which makes them readily understood by, and fit with the strategy of, the entire pharma organisation and its leadership”

This is Taylor’s first agency role, after serving the pharmaceutical industry for over 25 years, and will lead an experienced team of ex-pharma industry personnel, including Dr Scott Purdon, the former director of government affairs and policy at Gilead, ViiV Healthcare and GSK.

Con Franklin is Ketchum's new healthcare MD

Con Franklin

Con Franklin (pictured) has joined communications consultancy Ketchum as its managing director of healthcare, succeeding Kate Paxton who has returned to Ketchum’s US-based office.

Franklin will be based in London where he will grow the firm’s healthcare offering and providing senior counsel to clients.

Franklin’s new role will also position him as a mentor, developing the skills of those who join the comms consultancy.

He joins from FTI Consulting, where he most recently served as managing director of health and life sciences, and brings more than 18 years of experience from across the pharmaceutical and med-tech industries.

Commenting on his new role, Franklin said: “The global healthcare environment is in a constant state of change as organisations seek to innovate and bring solutions to patients based on sustainable outcomes and value ‘beyond the product'.

“Ketchum brings a powerful blend of deep sector knowledge, data-backed insight and creativity to help its clients thrive in this fast-moving sector. I'm thrilled to be joining the team and look forward to helping build on such an enviable track record.”

Uptake Strategies expand team

Healthcare marketing and commercial consultancy Uptake Strategies has bolstered its team with the addition of four new hires.

Strengthening the client support team are Lauren Tyson and Elizabeth Bolivar, who joins as account executive and digital marketing executive, respectively.

Trudie Loveridge

Meanwhile, Trudie Loveridge (pictured above) and Ian Dane take up roles at the company’s consulting team.

Loveridge has previously worked for GlaxoSmithKline as its marketing manager, while Dane has served as UK and Northern Europe business unit director, diabetes for Eli Lilly.

Article by
Gemma Jones

20th September 2018

From: Marketing



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...